Porcine UL-16 Binding Protein 1 Is Not a Functional Ligand for the Human Natural Killer Cell Activating Receptor NKG2D.
NKG2D
ULBP-1
gene editing
immune rejection
natural killer (NK) cell
xenotransplantation
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
01
10
2023
revised:
06
11
2023
accepted:
06
11
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Natural killer (NK) cells play a vital role in xenotransplantation rejection. One approach to induce NK cell immune tolerance is to prevent the NK cell-mediated direct killing of porcine cells by targeting the interaction of the activating receptor NKG2D and its ligands. However, the identity of porcine ligands for the human NKG2D receptor has remained elusive. Previous studies on porcine UL-16 binding protein 1 (pULBP-1) as a ligand for human NKG2D have yielded contradictory results. The goal of the present study was to clarify the role of pULBP-1 in the immune response and its interaction with human NKG2D receptor. To accomplish this, the CRISPR/Cas9 gene editing tool was employed to disrupt the porcine
Identifiants
pubmed: 37998322
pii: cells12222587
doi: 10.3390/cells12222587
pmc: PMC10670462
pii:
doi:
Substances chimiques
Receptors, Natural Killer Cell
0
NK Cell Lectin-Like Receptor Subfamily K
0
Ligands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA082709
Pays : United States
Organisme : NIDDK NIH HHS
ID : U54 DK106846
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI164002
Pays : United States
Références
Xenotransplantation. 2008 Sep-Oct;15(5):321-32
pubmed: 19134162
Mol Immunol. 2005 Apr;42(6):665-71
pubmed: 15781110
Clin Diagn Lab Immunol. 2001 Nov;8(6):1131-5
pubmed: 11687452
Xenotransplantation. 2015 Jan-Feb;22(1):20-31
pubmed: 25178170
Nat Immunol. 2000 Aug;1(2):119-26
pubmed: 11248803
Transplant Proc. 2000 Aug;32(5):936-7
pubmed: 10936282
Science. 1999 Jul 30;285(5428):727-9
pubmed: 10426993
J Pathol. 2016 Jan;238(2):288-99
pubmed: 26365762
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
Xenotransplantation. 2008 Mar-Apr;15(2):136-44
pubmed: 18447887
Front Immunol. 2022 Aug 22;13:941880
pubmed: 36072599
Transpl Int. 2016 Apr;29(4):443-52
pubmed: 26615051
Xenotransplantation. 2007 Mar;14(2):126-34
pubmed: 17381687
Immunology. 2010 Aug;130(4):545-55
pubmed: 20406306
3 Biotech. 2018 Jan;8(1):70
pubmed: 29354381
Kidney Int. 2019 Jan;95(1):188-198
pubmed: 30396694
J Immunol. 2006 Aug 15;177(4):2146-52
pubmed: 16887974
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Lancet. 2023 Jul 29;402(10399):397-410
pubmed: 37393920
Immunity. 2001 Feb;14(2):123-33
pubmed: 11239445
Front Immunol. 2020 Jan 23;10:3060
pubmed: 32038617
J Immunol. 1997 Oct 1;159(7):3655-61
pubmed: 9317166
Curr Opin Immunol. 1993 Aug;5(4):503-10
pubmed: 8216925
Transpl Immunol. 1996 Dec;4(4):265-70
pubmed: 8972555
Front Immunol. 2023 Jul 17;14:1217809
pubmed: 37529053
Tissue Antigens. 2001 Jan;57(1):55-65
pubmed: 11169259
Am J Transplant. 2002 Apr;2(4):314-22
pubmed: 12118852
N Engl J Med. 2022 Jul 7;387(1):35-44
pubmed: 35731912
J Immunol. 2004 Jun 15;172(12):7235-8
pubmed: 15187097
J Immunol. 2005 Oct 15;175(8):5463-70
pubmed: 16210654
Transplantation. 2009 Jan 15;87(1):35-43
pubmed: 19136889
Immunity. 2000 Jun;12(6):721-7
pubmed: 10894171
Cell Reprogram. 2010 Oct;12(5):599-607
pubmed: 20936908
J Exp Med. 2013 Jun 3;210(6):1065-8
pubmed: 23733834
Sci Rep. 2021 Jun 23;11(1):13131
pubmed: 34162938
J Immunol. 1997 Sep 1;159(5):2318-26
pubmed: 9278321
Science. 2013 Feb 15;339(6121):819-23
pubmed: 23287718
Hum Immunol. 2000 Nov;61(11):1066-73
pubmed: 11137209